Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Orthostatic hypotension, Low red blood cell count (anemia), Hypoglycemia, and Decreased glomerular filtration rate.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 1 | Low red blood cell count (anemia) |
CYB561 encodes cytochrome b561 (251 aa). Transmembrane reductase that probably uses ascorbate as an electron donor to reduce Fe(3+) into Fe(2+) and could play a role in iron transport. Highest expression in Pituitary (101.0 TPM) and Minor Salivary Gland (74.7 TPM).
Orthostatic hypotension 2 is associated with mutations in the CYB561 gene on chromosome 17.
CYB561 is classified as a druggable target with score 10.4.
Genetic testing for CYB561 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for orthostatic hypotension 2 has been reported in the published literature.
Phenotype severity distribution: 4 always present features.
No clinical trials have been registered for orthostatic hypotension 2.
203 publications have been identified in PubMed for orthostatic hypotension 2. Kisho has analyzed 85 by research type. Research spans Review / Meta-Analysis (40%), Epidemiology / Natural History (39%), and Clinical Trial Publication (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 34 | 40% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 12:49 AM UTC
Online Mendelian Inheritance in Man
1 |
Decreased glomerular filtration rate |
Disease patterns and progression
33 |
39% |
Clinical study results | 11 | 13% |
Testing and diagnosis research | 4 | 5% |
Laboratory research | 3 | 4% |
Savigamin C (2026). [PMID: 41668453](https://pubmed.ncbi.nlm.nih.gov/41668453/). *Ann Med*. [Clinical Trial Publication]
Heerspink HJL (2026). [PMID: 41428405](https://pubmed.ncbi.nlm.nih.gov/41428405/). *Clin J Am Soc Nephrol*. [Clinical Trial Publication]
McGarvey C (2026). [PMID: 41538292](https://pubmed.ncbi.nlm.nih.gov/41538292/). *Kidney360*. [Epidemiology / Natural History]
Novak P (2026). [PMID: 41576003](https://pubmed.ncbi.nlm.nih.gov/41576003/). *PLoS One*. [Epidemiology / Natural History]
Alsararatee HH (2026). [PMID: 41762103](https://pubmed.ncbi.nlm.nih.gov/41762103/). *Br J Hosp Med (Lond)*. [Review / Meta-Analysis]
Goswami N (2026). [PMID: 41021767](https://pubmed.ncbi.nlm.nih.gov/41021767/). *Physiol Rev*. [Review / Meta-Analysis]
Chiaro G (2026). [PMID: 40397689](https://pubmed.ncbi.nlm.nih.gov/40397689/). *Brain*. [Epidemiology / Natural History]
Liu Z (2026). [PMID: 41606321](https://pubmed.ncbi.nlm.nih.gov/41606321/). *Nature*. [Epidemiology / Natural History]
Ishikawa J (2026). [PMID: 41918339](https://pubmed.ncbi.nlm.nih.gov/41918339/). *Geriatr Gerontol Int*. [Review / Meta-Analysis]
Robbins NM (2026). [PMID: 42114076](https://pubmed.ncbi.nlm.nih.gov/42114076/). *Neurol Clin Pract*. [Review / Meta-Analysis]